Trivascular Technologies Stock Price, News & Analysis (NASDAQ:TRIV)

$5.87 0.00 (0.00 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$5.87
Today's Range$5.87 - $5.87
52-Week Range$3.98 - $11.49
VolumeN/A
Average Volume18,900 shs
Market Capitalization$120.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Trivascular Technologies (NASDAQ:TRIV)

Trivascular Technologies logoTrivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company's solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive TRIV News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryN/A
SectorMedical Devices & Implants
SymbolNASDAQ:TRIV
CUSIPN/A
Phone+1-707-5438800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($2.88)
Net IncomeN/A
Net Margins-143.61%
Return on Equity-766.90%
Return on Assets-66.97%

Miscellaneous

EmployeesN/A
Outstanding Shares20,520,000

Trivascular Technologies (NASDAQ:TRIV) Frequently Asked Questions

What is Trivascular Technologies' stock symbol?

Trivascular Technologies trades on the NASDAQ under the ticker symbol "TRIV."

How were Trivascular Technologies' earnings last quarter?

Trivascular Technologies Inc (NASDAQ:TRIV) announced its quarterly earnings results on Monday, November, 9th. The medical device company reported ($0.66) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.71) by $0.05. The medical device company had revenue of $9.50 million for the quarter, compared to analyst estimates of $9.28 million. Trivascular Technologies had a negative net margin of 143.61% and a negative return on equity of 766.90%. The firm's revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.69) earnings per share. View Trivascular Technologies' Earnings History.

Who are some of Trivascular Technologies' key competitors?

How do I buy Trivascular Technologies stock?

Shares of Trivascular Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trivascular Technologies' stock price today?

One share of Trivascular Technologies stock can currently be purchased for approximately $5.87.

How big of a company is Trivascular Technologies?

Trivascular Technologies has a market capitalization of $120.75 million.

How can I contact Trivascular Technologies?

Trivascular Technologies' mailing address is 3910 Brickway Blvd, SANTA ROSA, CA 95403-1070, United States. The medical device company can be reached via phone at +1-707-5438800.


MarketBeat Community Rating for Trivascular Technologies (TRIV)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Trivascular Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trivascular Technologies (NASDAQ:TRIV) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Trivascular Technologies (NASDAQ:TRIV) Earnings History and Estimates Chart

Earnings by Quarter for Trivascular Technologies (NASDAQ:TRIV)

Trivascular Technologies (NASDAQ TRIV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015Q3($0.71)($0.66)$9.28 million$9.50 millionViewN/AView Earnings Details
8/4/2015Q215($0.73)($0.73)$8.78 million$9.70 millionViewN/AView Earnings Details
5/5/2015Q115($0.68)($0.77)$8.48 million$9.00 millionViewListenView Earnings Details
3/3/2015Q414($0.65)($0.72)$9.54 million$9.10 millionViewListenView Earnings Details
11/10/2014Q314($0.63)($0.69)$7.90 million$7.88 millionViewN/AView Earnings Details
8/6/2014Q214($0.66)($0.87)$7.54 million$7.80 millionViewN/AView Earnings Details
5/14/2014Q1 14($1.10)($1.17)$6.90 million$7.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Trivascular Technologies (NASDAQ:TRIV) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Trivascular Technologies (NASDAQ:TRIV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Trivascular Technologies (NASDAQ TRIV) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Trivascular Technologies (NASDAQ:TRIV)

Trivascular Technologies (NASDAQ TRIV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/22/2014Douglas A RoederDirectorBuy833,333$12.00$9,999,996.00View SEC Filing  
4/22/2014Enterprise Associates 12 NewMajor ShareholderBuy583,333$12.00$6,999,996.00View SEC Filing  
4/22/2014James E FlynnInsiderBuy1,065,000$12.01$12,790,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Trivascular Technologies (NASDAQ TRIV) News Headlines

Source:
DateHeadline
Contrasting ConforMIS (CFMS) and Trivascular Technologies (TRIV)Contrasting ConforMIS (CFMS) and Trivascular Technologies (TRIV)
www.americanbankingnews.com - November 20 at 11:19 AM
Endologix Appoints John Onopchenko as Chief Operating OfficerEndologix Appoints John Onopchenko as Chief Operating Officer
finance.yahoo.com - October 19 at 10:00 AM
Form 8-K ENDOLOGIX INC /DE/ For: Oct 19Form 8-K ENDOLOGIX INC /DE/ For: Oct 19
www.streetinsider.com - October 19 at 10:00 AM
Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical AffairsSecond Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
www.businesswire.com - October 19 at 10:00 AM
Financial Analysis: Trivascular Technologies (TRIV) and St Jude Medical (STJ)Financial Analysis: Trivascular Technologies (TRIV) and St Jude Medical (STJ)
www.americanbankingnews.com - October 7 at 6:30 PM
St Jude Medical (STJ) and Trivascular Technologies (TRIV) Head to Head ContrastSt Jude Medical (STJ) and Trivascular Technologies (TRIV) Head to Head Contrast
www.americanbankingnews.com - September 30 at 6:26 AM
Trivascular Technologies (TRIV) versus Glaukos Corporation (GKOS) Critical ContrastTrivascular Technologies (TRIV) versus Glaukos Corporation (GKOS) Critical Contrast
www.americanbankingnews.com - August 26 at 6:22 PM
Cerus Corporation (CERS) vs. Trivascular Technologies (TRIV) Head-To-Head ComparisonCerus Corporation (CERS) vs. Trivascular Technologies (TRIV) Head-To-Head Comparison
www.americanbankingnews.com - August 26 at 8:29 AM
Obalon Therptcs (OBLN) & Trivascular Technologies (TRIV) Financial SurveyObalon Therptcs (OBLN) & Trivascular Technologies (TRIV) Financial Survey
www.americanbankingnews.com - August 24 at 8:10 PM
Analyzing Cerus Corporation (CERS) and Trivascular Technologies (TRIV)Analyzing Cerus Corporation (CERS) and Trivascular Technologies (TRIV)
www.americanbankingnews.com - August 12 at 12:30 AM
Trivascular Technologies (NASDAQ:TRIV) vs. Cerus Corporation (CERS) Head-To-Head ComparisonTrivascular Technologies (NASDAQ:TRIV) vs. Cerus Corporation (CERS) Head-To-Head Comparison
www.americanbankingnews.com - August 3 at 12:34 AM
TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquTRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acqu
biz.yahoo.com - February 3 at 5:23 PM
TriVascular Technologies, Inc. (TRIV)TriVascular Technologies, Inc. (TRIV)
biz.yahoo.com - January 17 at 7:47 PM
TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementTRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - November 9 at 4:21 PM
Q3 2015 TriVascular Technologies Inc Earnings Release - After Market CloseQ3 2015 TriVascular Technologies Inc Earnings Release - After Market Close
biz.yahoo.com - November 9 at 7:07 AM

SEC Filings

Trivascular Technologies (NASDAQ:TRIV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Trivascular Technologies (NASDAQ TRIV) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.